David Lucchino joins AdvaMed board
This article was originally published in Clinica
US industry association AdvaMed has elected David Lucchino, CEO of Semprus BioSciences, to its board of directors. Mr Lucchino will serve on AdvaMed's International Policy Committee, which aims to promote and improve access to medical technology in countries including Japan, Germany, France and the UK. He is also a member of the Emerging Company Issues subcommittee for AdvaMed's 2011 Medtech Conference, to be held in Washington, DC in September. AdvaMed is the world's largest trade association and represents around 400 medical device and diagnostics manufacturers. Cambridge, Massachusetts-based Semprus is a venture-funded spin-out of the Massachusetts Institute of Technology, which is developing a surface modification designed to reduce the attachment of particles such as bacteria and fungi to implanted medical devices.